This chapter analyses the Q-Linea project, an innovation for a new type of diagnostic technology for rapid characterisation of bloodstream infections. Q-Linea's main engagement is the development of a new type of diagnostic technology for rapid characterisation of bloodstream infections, based on DNA and protein detection. The theoretical points of departure of this project are the IMP approach and the key assumptions of resource heterogeneity and an interactive business landscape. The Q-Linea innovation journey stretches across an academic development setting and an emerging commercial producing and using setting and the interplay with a related accounting system. The Q-Linea innovation journey began with research carried out at the university's Rudbeck Laboratory, led by Professor Ulf Landegren. When the Q-Linea company was established in 2008, the initial business idea was to use the scientific advancements made at Rudbeck Laboratory as the base of Olink IP's along with the patents to develop and produce detection systems for the military industry.